Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Chris A. Yasenchak"'
Autor:
Jeff P. Sharman, Michael Boxer, Michael J. Hawkins, Jing Hu, Steve Abella, Leonard M. Klein, Kathryn S. Kolibaba, Chris A. Yasenchak, Meihua Wu
Small-molecule inhibitors of kinases involved in B-cell receptor signaling are an important advance in managing lymphoid malignancies. Entospletinib (GS-9973) is an oral, selective inhibitor of spleen tyrosine kinase. This multicenter, phase 2 study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::185fc1aec697bc2af87845a46c38f1a7
https://europepmc.org/articles/PMC4401348/
https://europepmc.org/articles/PMC4401348/
Autor:
Ahmad Awada, A. Douglas Laird, Geoffrey I. Shapiro, Patrick Schöffski, Sara M. Tolaney, Hovav Nechushtan, Chris A. Yasenchak, Eric P. Winer, Bridget O’Keeffe, I. G. Ron
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, 160 (2
Breast cancer research and treatment, 160 (2
Purpose: Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEGFR2, AXL, and other tyrosine kinases, was assessed in a cohort of metastatic breast cancer (MBC) patients in a phase II randomized discontinu